Middle East and Africa Vaccine Contract Manufacturing Market

Middle East and Africa Vaccine Contract Manufacturing Market Size

The size of the Middle East and Africa vaccine contract manufacturing market was worth USD 104 million in 2024. The regional market is anticipated to grow at a CAGR of 8.80% from 2025 to 2033 and be worth USD 222 million by 2033 from USD 114 million in 2025.

MARKET DRIVERS

Rising Government Support and Growing Demand for Novel Vaccines

Increasing government support for the development of healthcare infrastructure in some of the developing countries of Middle East and Africa is one major factor propelling the growth vaccine contract manufacturing market. Growing demand for the invention of vaccines and contract manufacturing are escalating market growth. Different bacterial and viral infections are regularly increasing, augmenting market demand. Expansion of population base amid the developing countries and growing support from the public and private organizations impels market growth. Escalating urbanization and industrialization is likely to boost the market. Mounting massive demand from different the Middle East & African countries for the launch of novel vaccines is to enlarge the market portfolio.

MARKET RESTRAINTS

High Vaccination Costs and Lengthy Approval Procedures

The vaccination cost is prohibitive, which is one of the major factors hindering the market growth. Strict rules and guidelines and lengthy approval procedures by government organizations for new products hamper the market demand.

REPORT COVERAGE

REGIONAL ANALYSIS

Geographically, the Halal vaccine market is a vast untapped area in this region. Also, because of various policy changes in regional governments, a steady increase is expected regarding this market. Middle East & Africa are expected to have a sluggish growth rate in the vaccine coverage market. Surging unmet needs for vaccination, the country's government policies and international bodies like the World Health Organization (WHO) are escalating the market demand. South Africa is leading the vaccine contract manufacturing market with the largest share. Huge funds and investments from International key players and increasing support from philanthropy organizations, including few vaccines among the national vaccine of many countries in Middle East and Africa, are likely to escalate the market growth. International healthcare organizations taking part in different vaccination programs are expected to influence the market growth in vaccine contract manufacturing. Moreover, advantages associated with the cost in infrastructure, operational benefits, and reduced time are propelling the market growth. UAE, Saudi Arabia, KSA, and the rest of Middle East and Africa are projected to a substantial increase in the vaccine contract manufacturing market.

KEY MARKET PLAYERS

Major manufacturing companies in the Middle East and Africa vaccine contract manufacturing market are GSK, SPIMANCO, Pfizer, Tabuk, Novartis, Jamjoom, Astra, Julphar, MSD, and Janssen.

MARKET SEGMENTATION

This research report on the Middle East and Africa vaccine contract manufacturing market has been segmented and sub-segmented into the following categories:

By Service Type:

• Bulk Product
• Fill Finish

By Product Type:

• Single Vaccine
  • Influenza Virus
  • Ebola Virus
  • Chickenpox
  • Tetanus
  • Tuberculosis
  • Polio
  • Smallpox
  • Others
• Combination Type

By Vaccine Type:

• Inactivated Vaccines
• Conjugate Vaccines
• Live Attenuated Vaccines
• Toxoid Vaccines
• Recombinant Vector Vaccines
• Subunit Vaccines
• Synthetic Vaccines

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of Middle East and Africa